Zion Market Research has published a new report titled “Amyotrophic Lateral Sclerosis Treatment Market by Treatment (Stem Cell Therapy, Medication, and Others) and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025” According to the report, global demand for amyotrophic lateral sclerosis treatment market was valued at approximately USD 538.9 Billion in 2018, and is expected to generate revenue of around USD 783.6 Billion by end of 2025, growing at a CAGR of around 5.6% between 2019 and 2025.
Amyotrophic Lateral Sclerosis (ALS) is a disorder that results in the demise of neurons that regulate the volunteer muscles. ALS involves muscle twitching, stiffness in muscles and steadily deteriorating paleness due to muscles diminishing in size. The precise cause of ALS is still unknown. Though, factors like environment and genetics are regarded most common.
Get Access to the FREE sample report @ https://www.zionmarketresearch.com/sample/amyotrophic-lateral-sclerosis-treatment-market
Factors such as growing geriatric population internationally, rising consciousness regarding ALS, rising prevalence of ALS, and introduction of new treatment choices will act as major driving factors in the growth of global amyotrophic lateral sclerosis treatment market. Scientific advancements and growing awareness in emerging regions will present an opportunity for the market players in the amyotrophic lateral sclerosis treatment market. Nonetheless, elevated cost of ALS management and lack of knowledgeable medical professionals will restrict the growth of global amyotrophic lateral sclerosis treatment market.
The global amyotrophic lateral sclerosis treatment market has been split into treatment, distribution channel. Based on treatment, amyotrophic lateral sclerosis treatment market has been segmented into stem cell therapy, medication, and others. The medication segment accounted for the highest market share in 2018 owing to recent FDA approvals.
The distribution channel segment has been divided into retail pharmacies, hospital pharmacies, and others. The retail pharmacies segment is expected to exhibit highest CAGR during the forecast period.
Regionally, the thoracic drainage devices market is segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa North America will be foremost region through the forecast time. U.S. will be the leading country in the North America region owing to high awareness, presence of latest healthcare setup, and recent FDA approvals for ALS medications. Europe will be the next key market. The crucial reasons are increasing geriatric population and favorable reimbursement scenario. Asia Pacific will develop at the highest growth rate owing to increasing awareness about ALS and growing geriatric population in Japan and China. Latin America region will proliferate at a remarkable rate through the projected time. Middle East & Africa region will display positive development in the projected time-frame.
The report also includes detailed profiles of key players such as Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, BrainStorm Therapeutics, AB Science, Biogen Inc., F.Hoffmann-La Roche AG, Corestem, Biohaven Pharmaceutical, AB Science, Ionis Pharmaceuticals, Inc., and Sun Pharmaceutical among others.
This report segments the Global Amyotrophic Lateral Sclerosis Treatment Market as follows:
Global Amyotrophic Lateral Sclerosis Treatment Market: By Treatment
Global Amyotrophic Lateral Sclerosis Treatment Market: By Distribution Channel
Global Amyotrophic Lateral Sclerosis Treatment Market: By Region
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/amyotrophic-lateral-sclerosis-treatment-market